Factors predictive of thrombotic events in LUMINA, a multi-ethnic cohort of SLE patients (LXXII)

Rheumatology

Volumn 49, Issue 9, 2010, Pages 1720-1725

  Burgos, Paula I ^a,b   McGwin Jr , Gerald ^c,d   Reveille, John D ^e   Vilá, Luis M ^f   Alarcón, Graciela S ^a  

^a The University of Alabama at Birmingham   (United States)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^c Kentucky   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF PUERTO RICO   (Puerto Rico)

Author keywords

Risk factors; Systemic lupus erythematosus; Thrombotic events

Indexed keywords

GLUCOCORTICOID;

ADOLESCENT; ADULT; AFRICAN AMERICAN; ARTERY THROMBOSIS; ARTICLE; CAUCASIAN; CIGARETTE SMOKING; COHORT ANALYSIS; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE PREDISPOSITION; ETHNICITY; FEMALE; GROUPS BY AGE; HEALTH INSURANCE; HISPANIC; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POVERTY; PREDICTOR VARIABLE; PRIORITY JOURNAL; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; TIME; VEIN THROMBOSIS;

ADULT; AFRICAN AMERICANS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SOCIOECONOMIC FACTORS; THROMBOSIS; UNITED STATES; YOUNG ADULT;

EID: 77955836323     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq140     Document Type: Article

References (23)

1. Somers E, Magder LS, Petri M. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. J Rheumatol 2002;29:2531-6.
2. Trager J, Ward MM. Mortality and causes of death in systemic lupus erythematosus. Curr Opin Rheumatol 2001;13:345-51.
3. Drenkard C, Villa AR, Alarcón-Segovia D, Perez-Vazquez ME. Influence of the antiphospholipid syndrome in the survival of patients with systemic lupus erythematosus. J Rheumatol 1994;21:1067-72.
4. Ho KT, Ahn CW, Alarcón GS, et al. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events. Rheumatology 2005;44:1303-7.
5. Tektonidou MG, Sotsiou F, Nakopoulou L, Vlachoyiannopoulos PG, Moutsopoulos HM. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. Arthritis Rheum 2004;50:2569-79.
6. Petri M. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus 1996;1(5 Suppl):S16-22.
7. Alarcon GS, Friedman AW, Straaton KV et al. Systemic lupus erythematosus in three ethnic groups: III. A comparison of characteristics early in the natural history of the LUMINA cohort. LUpus in MInority populations: NAture vs. Nurture. Lupus 1999;8:197-209.
8. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
9. Reveille JD, Moulds JM, Ahn C et al. Systemic lupus erythematosus in three ethnic groups: I. The effect of HLA-class II, C4 and CR1 alleles, socioeconomic factors and ethnicity on the onset of disease. Arthritis Rheum 1998;41:1161-72.
10. Gladman DD, Urowitz MB, Goldsmith CH et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:809-13.
11. U.S. Department of Commerce, Bureau of the Census. Current population reports, Series P-23, No. 28 and Series P-60, No. 68 and subsequent years. Washington, DC: Housing and Household Economic Statistics Division, 1995.
12. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989;32:1107-18.
13. Costenbader KH, Daniel JK, Peerzada J et al. Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis. Arthritis Rheum 2004;50:849-57.
14. Jay SJ. Cigarette smoking: risk factor for venous thromboembolic disease? Arch Intern Med 1998;158:2315-23.
15. Miller GJ, Bauer KA, Cooper JA, Rosenberg RD. Activation of the coagulant pathway in cigarette smokers. Thromb Haemost 1998;79:549-53.
16. Manzi S, Meilahn EN, Rairie JE et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol 1997;145:408-15.
17. Finazzi G, Brancaccio V, Moia M et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian registry. Am J Med 1996;100:530-6.
18. Cervera R, Piette JC, Font J et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002;46:1019-27.
19. Simantov R, Lasala JM, Lo SK et al. Activation of cultured vascular endothelial-cells by antiphospholipid antibodies. J Clin Invest 1995;96:2211-9.
20. Roman MJ, Shanker BA, Davis A et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2399-406.
21. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992;93:513-9.
22. Siso A, Ramos-Casals M, Bove A et al. Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. Lupus 2008;17:281-8.
23. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010;69:20-8.